Teva/Barr Merger Could Spell Opportunity For Smaller Generic Firms
Executive Summary
Several generic firms are calling the pending merger of Teva and Barr a positive development for the rest of the industry, saying that it will leave behind ample market share for smaller companies
You may also be interested in...
Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth
Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth
Credit Woes Hit Pharma
The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.